Tenderwize
Back to tender search

Pharmaceutical products with active ingredients Glecaprevir and Pibrentasvir (ATC: J05AP57)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Apr 29, 2027 · 255 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Glecaprevir und Pibrentasvir (ATC: J05AP57)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

No estimated contract value, budget, or framework maximum is provided, making it impossible to assess financial opportu...

The contract can be terminated if the buyer launches exclusive tenders for the same active ingredients during the contr...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Entering into non-exclusive discount agreements for pharmaceutical products containing Glecaprevir and Pibrentasvir
  • Open-house model: any qualified pharmaceutical company can join at any time
Show full summary

Non-exclusive discount contract opportunity under an 'open-house model' for pharmaceutical products containing Glecaprevir and Pibrentasvir (ATC: J05AP57), issued by AOK Sachsen-Anhalt. Qualified pharmaceutical companies can enter into contracts at any time until 30 April 2027. The contract runs for a maximum of 24 months until 30 June 2027. No estimated value is provided. The notice clarifies it is not a public procurement under GWB but is published for transparency.

Risks

No estimated contract value, budget, or framework maximum is provided, making it impossible to assess financial opportu...

The contract can be terminated if the buyer launches exclusive tenders for the same active ingredients during the contr...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies

Administrative

  • Request participation documents from the contact address
  • Complete and sign the participation documents

Buyer

Location

Magdeburg, DEU

Buyer profile

Open profile

Identifier

DE258393558

Activity

Health

Lots (1)

LOT-0001

Pharmaceutical products with active ingredients Glecaprevir and Pibrentasvir (ATC: J05AP57)

Non-exclusive discount agreements for finished medicinal products with the active ingredients Glecaprevir and Pibrentasvir. Any eligible pharmaceutical company can join at any time under uniform conditions. The contract duration is up to 24 months from 1 July 2025 to 30 June 2027. The contract may be terminated early if the buyer launches exclusive tenders for the same active ingredients.

SuppliesEU fundedElectronic submission

Location

DEE03, Germany

Duration

2 YEAR

Category

Pharmaceutical products

Deadline

Deadline Apr 29, 2027

Procurement Details

Publication date
18 May 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
318621-2025

Documents (1)

Similar tenders